Cumberland Pharmaceuticals To Announce Second Quarter 2020 Financial Results
Cumberland Pharmaceuticals Inc. (CPIX) will release its second quarter 2020 financial results and company update on August 11, 2020, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cumberland Pharmaceuticals Inc. (CPIX) will release its second quarter 2020 financial results and company update on August 11, 2020, after market close. A conference call is scheduled for the same day at 4:30 p.m. ET to discuss these results. The company focuses on developing and commercializing prescription brands in hospital acute care, gastroenterology, and oncology via targeted sales forces. Their FDA-approved products include Acetadote, Caldolor, Kristalose, and more, with ongoing Phase II programs for ifetroban in DMD, SSc, and AERD.
Positive
- Focus on specialty pharmaceuticals in high-demand areas like acute care and gastroenterology.
- Ongoing Phase II clinical programs for ifetroban targeting serious conditions.
Negative
- None.
Details
News Market Reaction – CPIX
The recorded move for CPIX in the trading session of this news was -0.30%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NASHVILLE, Tenn., Aug. 4, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release second quarter 2020 financial results and Company update after the market closes on Tuesday, Aug. 11, 2020. A conference call and live internet webcast will be held on Tuesday, Aug. 11, 2020, at 4:30 p.m. Eastern Time to discuss the results.
To participate in the call, please dial 877-303-1298 (for U.S. callers) or 253-237-1032 (for international callers). A rebroadcast of the teleconference will be available for one week and can be accessed by dialing 855-859-2056 (for U.S. callers) or 404-537-3406 (for international callers). The Conference ID for the rebroadcast is 2247089. The live webcast and rebroadcast can be accessed via Cumberland's website at http://investor.shareholder.com/cpix/events.cfm.
Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the delivery of high quality prescription brands to improve patient care. The Company develops, acquires and commercializes brands for the hospital acute care, gastroenterology and oncology market segments. These medical specialties are categorized by moderately concentrated prescriber bases that the Company believes can be penetrated effectively by targeted sales forces. The Company's portfolio of FDA-approved brands includes:
- Acetadote® (acetylcysteine) Injection, for the treatment of acetaminophen poisoning;
- Caldolor® (ibuprofen) Injection, for the treatment of pain and fever;
- Kristalose® (lactulose) for Oral Solution, a prescription laxative, for the treatment of chronic and acute constipation;
- Omeclamox®-Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori (H. pylori) infection and related duodenal ulcer disease;
- Vaprisol® (conivaptan) Injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia;
- Vibativ® (telavancin) Injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
- RediTrex® (methotrexate) Injection, for the treatment of active rheumatoid, juvenile idiopathic and severe psoriatic arthritis, as well as disabling psoriasis.
For more information on Cumberland's approved products, including full prescribing information, please visit links to the individual product websites, which can be found on the Company's website www.cumberlandpharma.com.
The Company has Phase II clinical programs underway evaluating its ifetroban product candidates in patients with cardiomyopathy associated with Duchenne Muscular Dystrophy ("DMD"), Systemic Sclerosis ("SSc"), and Aspirin-Exacerbated Respiratory Disease ("AERD").
View original content to download multimedia:http://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-to-announce-second-quarter-2020-financial-results-301105995.html
SOURCE Cumberland Pharmaceuticals Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.